Bioventus BVS Business Segments
| FY'25 | FY'24 | FY'23 | FY'22 | ||
|---|---|---|---|---|---|
| Total Net Sales by Business | |||||
| International Segment | $65.99M-0.7% | $66.47M+6.4% | $62.49M+9.9% | $56.87M— | |
| U.S. Segment | $502.1M-0.9% | $506.81M+12.7% | $449.86M-1.2% | $455.25M— | |
| Adjusted Earnings Before Interest, Taxes, Depreciation, Amortization And Other Non-Operating Items by Business | |||||
| International Segment | $15.31M+13.7% | $13.46M+32.0% | $10.19M-15.7% | $12.1M+22.0% | |
| U.S. Segment | $100.97M+5.8% | $95.42M+21.3% | $78.67M+39.2% | $56.51M-20.1% | |
| Adjusted other segment expense by Business | |||||
| International Segment | $188K+146% | -$405K-16.4% | -$348K-165% | $534K— | |
| U.S. Segment | $1.55M+539% | -$352K+62.6% | -$942K+10.0% | -$1.05M— | |
| Adjusted cost of sales by Business | |||||
| International Segment | $24.86M+2.8% | $24.19M-6.1% | $25.76M+29.8% | $19.85M— | |
| U.S. Segment | $113.82M-4.3% | $118.99M+8.3% | $109.89M-0.1% | $109.96M— | |
| Adjusted research and development expense by Business | |||||
| International Segment | $41K0.0% | $41K+32.3% | $31K-6.1% | $33K— | |
| U.S. Segment | $11.27M-14.3% | $13.14M+14.7% | $11.46M-37.5% | $18.33M— | |
| Adjusted general and administrative expense by Business | |||||
| International Segment | $9.33M-37.6% | $14.95M+21.7% | $12.29M+18.2% | $10.4M— | |
| U.S. Segment | $97.5M-0.1% | $97.59M+13.3% | $86.11M-8.0% | $93.57M— | |
| Adjusted selling expense by Business | |||||
| International Segment | $12.69M+12.9% | $11.23M-5.7% | $11.91M+5.5% | $11.29M— | |
| U.S. Segment | $152.08M-3.6% | $157.79M+12.5% | $140.28M-5.1% | $147.77M— | |
| Adjusted marketing expense by Business | |||||
| International Segment | $3.59M+19.4% | $3M+13.1% | $2.66M-0.4% | $2.67M— | |
| U.S. Segment | $24.92M+2.8% | $24.24M-0.7% | $24.4M-19.1% | $30.16M— | |
| Total Net Sales by Product | |||||
| Pain Treatments | $279.06M+6.8% | $261.29M+18.3% | $220.8M+2.1% | $216.33M-2.4% | |
| Restorative Therapies | $85.37M-30.4% | $122.74M-5.5% | $129.94M-11.9% | $147.51M+21.3% | |
| Surgical Solutions | $203.65M+7.6% | $189.26M+17.1% | $161.6M+9.0% | $148.28M+69.0% | |
| Concentration risk percentage by Product | |||||
| Product A | 36%+5.0pp | 31%+4.0pp | 27%+2.0pp | 25%-2.0pp | |
| Product B | 15%+2.0pp | 13%-1.0pp | 14%0.0pp | 14%-6.0pp | |
| Product C | 20%+2.0pp | 18%+1.0pp | 17%+2.0pp | 15%0.0pp | |
| Product D | 7%0.0pp | 7%-1.0pp | 8%-2.0pp | 10%-5.0pp | |
| Product E | 6%-1.0pp | 7%0.0pp | 7%0.0pp | 7%-1.0pp | |
| Total Net Sales by Geography | |||||
| International | $65.99M-0.7% | $66.47M+6.4% | $62.49M+9.9% | $56.87M+31.2% | |
| U.S. | $502.1M-0.9% | $506.81M+12.7% | $449.86M-1.2% | $455.25M+17.5% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How does Bioventus break its business down?
- Bioventus (BVS) reports total net sales by business across 2 parts — International Segment and U.S. Segment. Each is extracted from the segment footnotes and tracked over time.
- Where does Bioventus's segment data come from?
- Segment breakdowns are pulled from the segment footnotes in Bioventus's SEC filings (the XBRL dimensional tags), so every line ties back to a reported figure. Switch between quarterly, annual, and TTM, or open any segment for its full history.
